Evidence map›Paper›PMID 38562019›Full record

ArticleCancer medicine2024

Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC.

Shuo Yu, Hui Ren, Tingting Liu, Xiaoyan Han, Hui Guo, Qian Ning, Yang Li, Hong Zhou, Mingwei Chen, Tinghua Hu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Beyond the gap: moonlighting functions of connexins in cancer.Cell communication and signaling : CCS · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shuo YuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Hui RenDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Tingting LiuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.ORCID 0000-0003-1109-4404
Xiaoyan HanDepartment of General Surgery, Weifang People's Hospital, Weifang, Shandong, China.
Hui GuoDepartment of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Qian NingDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Yang LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Hong ZhouDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Mingwei ChenDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.ORCID 0000-0002-0418-1510
Tinghua HuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
First Affiliated Hospital of Xi'an Jiaotong University · CNWeifang People's Hospital · CN

Funding

Exploration and Innovation Project of First Affiliated Hospital of Xi'an Jiaotong University 2019ZYTS-05Natural Science Basic Research Plan in Shaanxi Province of China 2022JQ-791Shaanxi Provincial Key Research and Development Program 2021KW-51Special Fund for Personnel Training of Second Affiliated Hospital of Xi'an Jiaotong University RC(XM)202007
6 · The paper itself

Abstract

objectiveNon-small-cell lung cancer (NSCLC) is a deadly form of cancer that exhibits extensive intercellular communication which contributed to chemoradiotherapy resistance. Recent evidence suggests that arrange of key proteins are involved in lung cancer progression, including gap junction proteins (GJPs). METHODS AND

resultsIn this study, we examined the expression patterns of GJPs in NSCLC, uncovering that both gap junction protein, beta 2 (GJB2) and gap junction protein, beta 2 (GJB3) are increased in LUAD and LUSC. We observed a correlation between the upregulation of GJB2, GJB3 in clinical samples and a worse prognosis in patients with NSCLC. By examining the mechanics, we additionally discovered that nuclear factor erythroid-2-related factor 1 (NFE2L1) had the capability to enhance the expression of connexin26 and connexin 31 in the NSCLC cell line A549. In addition, the use of metformin was discovered to cause significant downregulation of gap junction protein, betas (GJBs) by limiting the presence of NFE2L1 in the cytoplasm.

conclusionThis emphasizes the potential of targeting GJBs as a viable treatment approach for NSCLC patients receiving metformin.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMetforminConnexinsGap JunctionsHumansNF-E2-Related Factor 1ConnexinsMetforminNFE2L1 protein, humanNF-E2-Related Factor 1gap junction proteinsmetforminNFE2L1NSCLCprognosis

Identifiers

PMID38562019
PMCPMC10985411
OpenAlexW4393486200

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.